Management of Aortic Stenosis (Guideline Recommendations)

Indications for Aortic Valve Replacement in Symptomatic Severe AS

All patients with symptomatic severe aortic stenosis should receive aortic valve replacement (surgical or transcatheter) because medical therapy alone results in ≈ 50 % mortality within 2–3 years (Class I, American College of Cardiology). 1
The three hallmark symptoms that trigger urgent valve replacement are angina, syncope (or near‑syncope), and heart‑failure‑related dyspnea (Class I, European Society of Cardiology). 2

Surgical‑Risk–Based Selection of Valve Replacement Modality

Prohibitive surgical risk (≥ 50 % predicted 30‑day mortality/irreversible morbidity, frailty, porcelain aorta, prior chest radiation, severe hepatic or pulmonary disease) → transcatheter aortic valve replacement (TAVR) is recommended (Class I, ACC). 1
High surgical risk (Society of Thoracic Surgeons score ≥ 8 %) → TAVR is a reasonable alternative to surgical AVR (Class IIa, ACC). 1
Intermediate or low surgical risk → either TAVR or surgical AVR is acceptable; decision should be made by a multidisciplinary Heart Team (Class IIa, ACC). 1

Management of Asymptomatic Severe AS

Class I Indications for Early AVR

Left‑ventricular ejection fraction < 50 % mandates AVR regardless of surgical risk (Class I, ESC). 2
Patients undergoing other cardiac surgery (e.g., coronary artery bypass grafting, aortic repair, or other valve procedures) should receive concomitant AVR (Class I, ACC). 1
Abnormal exercise stress‑test findings—significant systolic blood‑pressure fall (≥ 10–20 mmHg), development of symptoms, or markedly reduced exercise tolerance—warrant AVR (Class I, ESC). 2

Class IIa/IIb Considerations for AVR in Low‑Risk Asymptomatic Patients

Very severe AS (peak aortic jet velocity ≥ 5.0 m/s or mean gradient ≥ 60 mmHg) supports AVR (Class IIa, ACC/ESC). 1
Rapid progression (increase in jet velocity ≥ 0.3 m/s per year with severe valve calcification) favors early AVR (Class IIa, ESC). 2
Markedly elevated BNP (> 3 × age‑ and sex‑adjusted normal) is a trigger for AVR (Class IIa, ESC). 2
High‑demand occupations or lifestyles (e.g., commercial pilots, elite athletes) may justify AVR (Class IIb, ACC). 3
Registry data show that patients with LVEF < 55 % have higher mortality and that early surgical intervention reduces all‑cause mortality (observational evidence, ESC). 2

Role of Medical Therapy and Adjunctive Procedures

No drug therapy has been proven to halt or reverse AS progression; statins are not indicated (Class III, ACC). 1
Aggressive diuretics, vasodilators, and positive inotropes should be avoided before AVR because they can precipitate hemodynamic collapse (Class III, ACC). 1
Balloon aortic valvuloplasty is reserved for palliation in patients unsuitable for AVR or as a bridge to definitive surgery (Class IIb, ACC; supporting data from Circulation 2016). 4

Surveillance Strategy for Asymptomatic Patients

Asymptomatic individuals require regular clinical assessment and echocardiographic follow‑up (Class I, ACC). 4
A rise in aortic jet velocity of ≥ 0.3 m/s per year on serial imaging signals disease acceleration and should prompt re‑evaluation for AVR (Class IIa, ESC). 2
Exercise testing should be performed in apparently asymptomatic patients to uncover latent symptoms (Class IIa, ESC). 2

Critical Pitfalls to Avoid

Delaying AVR after symptom onset markedly reduces survival; prompt intervention is essential (Class I, ACC). 1
Missing a reduced LVEF (< 50 %) in an asymptomatic patient constitutes a missed indication for AVR (Class I, ESC). 2
Use of vasodilators or aggressive diuresis in severe AS patients awaiting surgery can cause hemodynamic instability (Class III, ACC). 1
Prescribing statins with the expectation of slowing AS progression is ineffective (Class III, ACC). 1
Exercise testing can unmask subtle symptoms in patients who consider themselves asymptomatic (Class IIa, ESC). 2

Management of Severe Aortic Stenosis

Patient Assessment and Classification

Severe aortic stenosis is defined by an aortic valve area ≤1.0 cm², peak velocity ≥4 m/sec, or mean gradient ≥40 mmHg, according to the American College of Cardiology and European Heart Journal guidelines 5, 6
Patients should be classified based on symptom status, left ventricular ejection fraction, flow status, and gradient, as recommended by the American College of Cardiology and European Heart Journal 5, 6, 7, 8

Management of Symptomatic Severe Aortic Stenosis

Valve replacement is indicated for all symptomatic patients with severe aortic stenosis, as recommended by the American College of Cardiology and European Heart Journal 5, 6, 7
Medical management alone is rarely appropriate for symptomatic patients, according to the American College of Cardiology 5, 9

Management of Asymptomatic Severe Aortic Stenosis

Watchful waiting with regular clinical and echocardiographic follow-up is appropriate for most asymptomatic patients with normal left ventricular function, as recommended by the American College of Cardiology 5
Valve replacement should be considered in asymptomatic patients with reduced left ventricular ejection fraction, very severe aortic stenosis, rapid progression of stenosis, or abnormal exercise test results, according to the American College of Cardiology and European Heart Journal 5, 9, 6, 10

Medical Therapy Components

Fluid management should maintain adequate preload and avoid excessive diuresis, as recommended by the European Heart Journal 11
Heart rate control should maintain adequate diastolic filling time and avoid tachycardia, according to the European Heart Journal 7, 11

Special Considerations

Non-cardiac surgery requires careful perioperative management with a multidisciplinary heart team approach, as recommended by the European Heart Journal 7
Low-flow, low-gradient aortic stenosis requires dobutamine stress echocardiography to distinguish true-severe from pseudo-severe aortic stenosis, according to the European Heart Journal 6, 8

Guideline Recommendations for Aortic Stenosis Management

Indications for Aortic Valve Replacement (AVR)

Symptomatic severe aortic stenosis (AS) mandates AVR (surgical or transcatheter) because medical therapy alone yields ≈50 % mortality within 2–3 years. – American College of Cardiology (ACC) Class I recommendation. 12
Class I indications for AVR in asymptomatic severe AS:
Class IIa indications for AVR in asymptomatic severe AS:
Class IIb indications for AVR in low‑risk asymptomatic patients:

Risk Stratification and Choice of Procedure

Prohibitive surgical risk (predicted 30‑day mortality ≥ 50 %): Transcatheter AVR (TAVR) is the recommended treatment. – ACC Class I. 12
High surgical risk (STS score ≥ 8 %): TAVR is a reasonable alternative to surgical AVR; decision should be made by a Heart Team, with a general preference for TAVR. – ACC Class IIa. 12
Intermediate or low surgical risk (STS score < 8 %): Either TAVR or surgical AVR is acceptable; selection is individualized by a multidisciplinary Heart Team. – ACC Class IIa. 12
Age‑based considerations (when risk is low/intermediate):

Contraindicated Medical Therapies

Statins are not indicated for slowing AS progression (Class III). – ACC. 12
Aggressive diuretics should be avoided in patients awaiting AVR because of risk of hemodynamic collapse (Class III). – ACC. 12
Vasodilators should be avoided before AVR due to potential destabilization (Class III). – ACC. 12
Positive inotropes should be avoided in patients awaiting AVR (Class III). – ACC. 12

Management of Low‑Flow, Low‑Gradient AS

Low‑flow, low‑gradient AS with reduced EF: Perform dobutamine stress echocardiography to assess flow reserve. If reserve is present, AVR should be performed (acceptable risk, outcome improvement). If reserve is absent, AVR may still be considered despite higher operative mortality, as it can improve EF and clinical status. – ESC Class IIa. [13][14]
Paradoxical low‑flow, low‑gradient AS with normal EF: Surgery is indicated only when symptoms are clearly present and comprehensive evaluation confirms significant valve obstruction. – ESC Class I. 13

Balloon Aortic Valvuloplasty

Balloon valvuloplasty is a Class IIb (limited) option for:

Surveillance of Asymptomatic Patients

Follow‑up schedule: Clinical assessment and echocardiography every 6 months when risk factors (e.g., rapid velocity increase, LV hypertrophy) are present. – ESC Class IIa. [15][16]

Heart Team and Institutional Requirements

Procedural setting: TAVR must be performed only in hospitals that have on‑site cardiac surgery capability. – ESC. [15][16]
Multidisciplinary Heart Team composition: cardiologists with valvular expertise, structural interventional cardiologists, imaging specialists, cardiovascular surgeons, and cardiovascular anesthesiologists. – ESC. [15][16]
Heart Team responsibilities: evaluate individual patient risk, technical/anatomic suitability, and align treatment with patient goals and life expectancy. – ESC (risk assessment) 16; ACC (technical suitability) 12.

Management of Severe Aortic Stenosis – Evidence‑Based Recommendations

Indications for Aortic Valve Replacement (AVR)

All patients with symptomatic severe aortic stenosis require aortic valve replacement (surgical or transcatheter) because medical therapy alone leads to ≈50 % mortality within 2–3 years. – American College of Cardiology (ACC) [17, 18]
Intervention is indicated for symptomatic severe AS regardless of surgical risk. – ACC [17, 18]
Medical management is appropriate only when non‑cardiac comorbidities limit life expectancy to <1 year or dominate the patient’s overall health status. – ACC [17, 18]

Risk Stratification and Choice of Intervention

Surgical‑risk category (STS‑PROM)	Recommended valve‑replacement strategy	Supporting citation
Prohibitive risk (≥50 % predicted 30‑day mortality, frailty, hostile chest, etc.)	Transcatheter AVR (TAVR)	— (no citation)
High risk (≥8 %)	TAVR preferred	ACC [17, 18]
Intermediate risk (4–8 %)	Either TAVR or surgical AVR (SAVR) – decision by multidisciplinary Heart Team	ACC [17, 18]
Low risk (<4 %)	SAVR strongly preferred, especially in patients < 65 years for durability	— (no citation)

Low‑Flow, Low‑Gradient Severe AS with Reduced Ejection Fraction

Dobutamine stress echocardiography is required to differentiate true‑severe from pseudo‑severe stenosis in low‑flow, low‑gradient AS with reduced EF. – ACC [17, 18]
When contractile reserve is present and true‑severe AS is confirmed, AVR is appropriate irrespective of surgical risk. – ACC [17, 18]
If stress testing suggests pseudo‑severe stenosis, medical management is appropriate. – ACC [17, 18]

Concomitant Coronary Artery Disease

For patients with severe AS and significant coronary disease requiring revascularisation, combined SAVR + CABG is appropriate. – ACC [19]
In intermediate/high surgical‑risk patients with less complex CAD (low SYNTAX score), catheter‑based revascularisation may be considered. – ACC [17]

Concomitant Valvular Disease

Primary mitral regurgitation does not improve after isolated AS correction; a concomitant or staged mitral procedure is required. – ACC [19]
Secondary mitral regurgitation may improve after isolated AVR, depending on LV dysfunction and leaflet tethering. – ACC [19]
Severe tricuspid regurgitation should be treated whenever feasible because it portends poor prognosis. – ACC [19, 20]

Bicuspid Aortic Valve with Ascending Aortic Aneurysm

When the ascending aorta measures ≥4.5 cm, simultaneous surgical repair of the valve and aorta should be considered. – ACC [19, 20]
Experience with TAVR in bicuspid anatomy remains limited. – ACC [19, 20]

Non‑Cardiac Surgery Considerations

In symptomatic severe AS requiring major non‑cardiac surgery, proceeding without addressing the valve is rarely appropriate due to markedly increased peri‑operative morbidity and mortality. – ACC [20]
Performing SAVR or TAVR before the non‑cardiac operation is appropriate. – ACC [20]
Balloon aortic valvuloplasty may be used as a temporising bridge to definitive AVR. – ACC [20]
For asymptomatic severe AS undergoing elective major surgery, a more conservative (no‑intervention) approach may be reasonable, although AVR (TAVR or SAVR) is also acceptable. – ACC [19, 20]

Heart‑Team Evaluation and Frailty

All decisions regarding valve replacement must involve a multidisciplinary Heart Team (cardiologists, interventionalists, surgeons, imaging specialists, anesthesiologists, and geriatrics when appropriate). – (general statement, no citation)
Frailty and comorbidities not captured by conventional risk scores should be incorporated into the Heart‑Team assessment. – ACC [18]